Author

Shizuka Origuchi

Observed names: Origuchi, Shizuka, S., Origuchi

Observed institution: Novartis Institutes for BioMedical Research

OpenAlex ID: A5034432167

A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events

2021 · Patrick Schöffski, Nicole Concin, et al. · Oncology Research and Treatment · 28

Abstract CT112: Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of FXX489 ([177Lu]Lu-NNS309) in patients with pancreatic, lung, breast and colorectal cancers

2025 · Ravit Geva, Daniel Juneau, et al. · Cancer Research · 2

Supplementary Material for: A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events

2021 · P., Schöffski, N., Concin, et al. · Figshare

Works count: 4

Citation count: 30

H-index: 2

I10-index: 1